ZimVie — Q4 2024 Earnings Presentation
18 slides from ZimVie's earnings presentation, Feb 26, 2025
Slide 1: A Global Dental Leader
A Global Dental Leader February 2025 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans
Slide 3: ZimVie: A Global Dental Leader
ZimVie: A Global Dental Leader Market-leading portfolio of premium implants, restorative implant solutions, biomaterials solutions, and digital dentistry technologies 8M Only 25% receive tooth replacement Focused on driving greater adoption of dental implants through training, education, and digital
Slide 4: Dental Implants: Portfolio Overview
Dental Implants: Portfolio Overview Premium implant portfolio catering to both routine and complex cases along with a full range of surgical tools and restorative components TSX® Implant System Launched in 2022, TSX Implants are designed to simplify procedures and optimize practice protocols to deli
Slide 5: Biomaterials: Portfolio Overview
Biomaterials: Portfolio Overview Biomaterial solutions that are used for bone and tissue regeneration, helping build a healthy site necessary for dental implant success to deliver aesthetic results Xenograft and Synthetic Bone Grafts Alternative to human-donor sourced bone with both xenograft and sy
Slide 6: Digital: Portfolio Overview
Digital: Portfolio Overview End-to-end solutions ranging from intraoral scanning technology to open architecture CAD/CAM systems, guided surgery solutions, and patient-specific restorations BellaTek® Patient Specific Restorative Solutions Patient-specific abutments, bars, implant bridges, and hybrid
Slide 7: Revitalizing the Portfolio with Recent Launches
Revitalizing the Portfolio with Recent Launches Dental Implants Biomaterials Digital Dentistry T3® PRO Implant Encode® Emergence Healing Abutment TSX® Implant Azure™ Multi-Platform Solutions Portfolio RegenerOss® Cortico–Cancellous Particulate RegenerOss® Bone Graft Plug Biotivity™ A/C Plus Membrane
Slide 8: Virtual Treatment Planning, Guided Surgical Kits, End-to-End Solutions
Virtual Treatment Planning Digitally Guided Surgical Kits End-to-End Solutions Save Time and Improve the Clinician and Patient Experience *Internal data AI facilitated restorative solutions require significantly fewer labor hours* ZimVie Encode Emergence workflow reduces chair time and saves one res
Slide 9: 2024 Achievements: Driving Leverage and Operationalization
2024 Achievements: Driving Leverage and Operationalization Continued reduction of corporate expenses following exit from Spine-related TSAs Substantially reduced debt to improve financial health and flexibility Streamlined operational profile Positioned to drive greater operating efficiency and free
Slide 10: Financial Profile & Outlook
Financial Profile & Outlook Q4 2024* FY 2025* Drivers of Progress Expanding portfolio adoption within large, underserved dental markets Reducing expense profile to improve margins Adjusted EBITDA $18.4M(1) $65M - $70M(2) Net Sales $111.5M $445M - $460M Best-in-class portfolio and commitment to ongoi
Slide 11: Appendix
Dp Appendix < ZimVie
Slide 12: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by
Slide 13: Reconciliation of Net Debt
As of December 31, 2024 2023 Non-current portion of debt $ 220,451 $ 508,797 Less: Cash and cash equivalents (74,974) (71,511) Net Debt $ 145,477 $ 437,286 Reconciliation of Net Debt Continuing Operations ($ in thousands)
Slide 14: Reconciliation of Adjusted Cost of Products Sold
For the Three Months Ended December 31 Percentage of Third Party Net Sales For the Year Ended December 31 Percentage of Third Party Net Sales 2024 2023 2024 2023 2024 2023 2024 2023 Cost of products sold, excluding intangible asset amortization $ (38,707) $ (42,573) (34.7%) (37.7%) $ (162,303) $ (16
Slide 15: Reconciliation of Adjusted R&D and Adjusted SG&A
For the Three Months Ended December 31 Percentage of Third Party Net Sales For the Year Ended December 31 Percentage of Third Party Net Sales 2024 2023 2024 2023 2024 2023 2024 2023 Research and development $ (6,621) $ (6,893) (5.9%) (6.1%) $ (26,905) $ (26,162) (6.0%) (5.7%) European union medical
Slide 16: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA Continuing Operations ($ in thousands) For the Three Months Ended December 31 For the Year Ended December 31, 2024 Continuing Operations of ZimVie Inc. 2024 2023 2024 2023 Net Sales Total Third Party Sales $ 111,521 $ 113,066 $ 449,749 $ 457,197 Related Party Sales
Slide 17: Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS
Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS Continuing Operations (in thousands, except per share data) [1] Restructuring activities to better position the organization and the expenses incurred were primarily related to employee termination benefits and professional fees. [2] Acqu
Slide 18: Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS
Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS Continuing Operations (in thousands, except per share data) [1] Restructuring activities to better position the organization and the expenses incurred were primarily related to employee termination benefits and professional fees. [2] Acqu